FAM153B

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, FAM153B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FAM153B data layer compared with 20 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher FAM153B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM153B expression acts as an unfavorable survival marker.

BLCA and LIHC are the cancer types where FAM153B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
BLCAOSMedianAll0.1830.720.00121view →
LIHCOSMedianAll0.1050.774.0043view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

FAM153B–BLCA (OS)

Kaplan–Meier survival curve for FAM153B mutant vs wild-type samples in BLCA.

Open the BLCA breakdown →

Exploration